In Amgen Inc. v. Hospira, Inc., [2019-1067, 2019-1102](December 16, 2019), the Federal Circuit affirmed the district court’s determination that Amgen’s U.S. Patent No. 5,856,298 was infringed and not invalid; fourteen batches of Hospira’s erythropoietin biosimilar drug product were not covered … Continue reading Substantial Evidence Supported Jury Verdict that not all Infringing Uses were Reasonably Telated to Developing and Submitting Information to the FDA